Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Providers
Hospitals
Practices
Retail
Health Tech
AI and Machine Learning
Digital Health
Telehealth
Payers
Regulatory
Finance
Special Reports
Fierce 50
Special Report
Awards Gala
Resources
Webinars
Fierce Events
Industry Events
Podcasts
Survey
Whitepapers
Events
Subscribe
Subscribe
Providers
Hospitals
Practices
Retail
Health Tech
AI and Machine Learning
Digital Health
Telehealth
Payers
Regulatory
Finance
Special Reports
Fierce 50
Special Report
Awards Gala
Resources
Webinars
Fierce Events
Industry Events
Podcasts
Survey
Whitepapers
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Bristol Myers Squibb
Providers
Mayo, LifePoint sue pharmas over 'pay for delay' agreements
Health systems say deals between Revlimid's owners, Celgene and Bristol-Myers Squibb, and other pharmas are anticompetitive and drive higher prices.
Dave Muoio
Oct 19, 2023 3:00pm
ConcertAI hits $1.9B valuation with $150M series C
Mar 30, 2022 7:15am
J&J to cut off 340B discounts to pharmacies starting in May
Mar 22, 2022 3:10pm
Safety net hospitals report early losses from pharma's 340B cuts
Jan 31, 2022 7:10am
Bristol Myers Squibb latest to roll out 340B restrictions
Jan 19, 2022 9:30am
NYU Langone wants to put NYC on the map as a biotech hub
Dec 17, 2019 8:57am